Australia's Starpharma hits 5-week high on UK relaunch of nasal spray

Starpharma Holdings

01/04/2022 03:13

** Shares of drug developer Starpharma Holdings  SPL.AX 
rise as much as 7.2% to A$0.970, their highest since Feb 23 
    ** Says its antiviral nasal spray Viraleze will relaunch in
the UK after co resolved queries raised last year by the
country's Medicines and Healthcare products Regulatory Agency
(MHRA)   urn:newsml:reuters.com:*:nASX29lvy7
    ** Says the product is expected to be available both online
and through LloydsPharmacy stores 
    ** Stock eyes best day since March 17, if gains hold, and is
on track for a second consecutive session of gains 
    ** Stock down ~32.5% this year, as of last close 

 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))